Objective: Breast cancer is the most common cancer in women. Trastuzumab is an effective breast cancer agent. The most significant side effect of trastuzumab is left ventricular systolic dysfunction. Selvester score calculated from 12-lead electrocardiography (ECG) has a proven accuracy in predicting left ventricular infarct area and scar volume. We aimed to determine its role in detection of left ventricular systolic dysfunction among trastuzumab-treated breast cancer patients. Methods: A total of 60 trastuzumab-treated patients were retrospectively included. The patients were grouped into two groups with trastuzumab-induced left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) <55%) (Group 1) and without (Group 2). The left ventricular systolic dysfunction group was divided into two subgroups: LVEF <50% and (Group 1a) and LVEF 50-54% (Group 1b). The Selvester score was compared between Group 1 and Group 2, and between Group 1a, Group 1b, and Group 2. The predictive role of Selvester score in trastuzumab-induced left ventricular systolic dysfunction was determined with univariate and multivariate analysis. Results: The mean age of the patients was 56.7±13.7 years. Twenty (21.1%) patients had trastuzumab-induced left ventricular systolic dysfunction. The Selvester score was similar between Group 1 and Group 2. Group 1a had a significantly greater Selvester score compared to Group 1b and Group 2 (p<0.05); however, Group 1b and Group 2 had similar Selvester scores (p>0.05). The Selvester score was significantly correlated with left ventricular systolic dysfunction in univariate analysis (r=0.189, p<0.05) but not in multivariate analysis. Conclusion: Selvester score may be useful especially for detecting severe trastuzumab-induced left ventricular systolic dysfunction.
INTRODUCTION
Breast cancer is the most common cancer in women, and it is associated with the highest number of cancer-related deaths in the same gender (1) . Although survival rates have been recently improved by surgery and chemotherapy regimens, the need for novel therapies remains. Trastuzumab is a monoclonal antibody against HE-2 protein and has a confirmed efficacy against metastatic and early breast cancers overexpressing HER-2 as monotherapy or in combination with other agents (2-7). Cardiotoxicity, particularly left ventricular systolic dysfunction, is the most important side effect of trastuzumab (8) . Trastuzumab-induced cardiotoxicity has been described with monotherapy and/or combination therapy (9) , with the risk particularly being particularly increased by a history of anthracycline use (10, 11) . Trastuzumab cardiotoxicity appears to be mediated by the inhibition of the human epidermal growth factor receptor 2, causing ATP depletion and loss of contractile properties and strength (12) ; however, other mechanisms involving immune destruction of cardiomyocytes have also been described (12, 13) .
Transthoracic echocardiography plays a central role in determining trastuzumab-induced left ventricular systolic dysfunction. However, it is operator dependent, costly, and time-consuming. Moreover, it is not always available, particularly in the emergency setting. Therefore, simpler tools are needed to determine trastuzumab cardiotoxicity. Twelve-lead electrocardiography (ECG) is a quick, relatively easy-to-interpret, cheap, and widely available non-invasive tool. It is less operator dependent, and has a high reproducibility. The Selvester score is a 12-lead ECG tool to indicate left ventricular infarct size and extent, particularly in the case of myocardial infarction (14) . The original Selvester score is composed of 54 criteria scored with a total of 32 points. A modified, simplified form of the Selvester score was developed later, consisting of 50 criteria with a total score of 31 points (15, 16) . ECG criteria in Selvester score include wave durations (Q or R), wave amplitude (R or S), and amplitude ratios (R/Q or R/S). The original score's each point roughly corresponds to 3% of left ventricular mass/volume, and the score provides the closest ECG approximation to infarct and scar volume of the left ventricle (16, 17) . To date, the role of the Selvester score has been shown for a number of disorders and conditions characterized by ventricular scarring, such as ischemic and non-ischemic cardiomyopathy (18, 19) , Chagas disease (20) , and acute myocardial infarction (21) . Nevertheless, to the best of our knowledge, the Selvester score has not been studied previously among breast cancer patients who were administered trastuzumab and developed left ventricular systolic dysfunction. Herein, we aimed to assess the Selvester score in 12-lead ECG in detecting left ventricular systolic dysfunction among breast cancer patients who received trastuzumab.
METHODS
Başkent University Institutional Review Board and Ethics Committee approved this study and Başkent University Research Fund supported the study (Project No: KA16/57). No informed consent was obtained from the patients since this was a retrospective study performed with screening of medical records. The patients who received trastuzumab between 01.01.2011 and 16.02.2016 were determined from among 726 patients who presented to our hospital's division of medical oncology and diagnosed with breast cancer. A total of 130 patients that received trastuzumab were identified. All the patients underwent serial clinical and echocardiographic cardiac examination after trastuzumab initiation. All the patients were examined by echocardiography after each trastuzumab course by expert echocardiographer physicians using a General Electric Vivid E9 (Horten, Norway) Echocardiography device. Left ventricular systolic dysfunction was considered as a left ventricular ejection fraction (LVEF) drop of at least 5% with a final LVEF dropping below 55% in symptomatic patients or a LVEF drop of at least 10% with a final LVEF dropping below 55% in asymptomatic patients (8) . The patients were deemed to have trastuzumab-induced left ventricular systolic dysfunction anytime when they were detected to have a drop in LVEF compared to baseline, as described above. Patients with previous left ventricular systolic dysfunction (LVEF<55%) and those with left ventricular systolic dysfunction attributable to other causes (acute myocardial infarction, cardiac ischemia, myocarditis, toxins, etc.) were excluded. Additionally, patients with left or right bundle branch block, left anterior or posterior fascicular block, left or right ventricular hypertrophy, preexcitation, low voltage, or ventricular pacing on 12-lead ECG were excluded. The Selvester score was calculated using standard 12-lead ECGs taken with the patient in supine position. The Selvester score was composed of 38 ECG criteria rated by 22 points, excluding the posterior V1 and V2 derivations included in the original score (Table 1 ) (22). Table 1 . The 38-criteria, 22-point, modified Selvester QRS-scoring system excluding the posterior V1 and V2 leads. If ≥2 criteria within the same gray-shaded box were met, only the criterion generating the highest number of points was considered. In each lead, the maximum lead score is seen within parenthesis
Lead
Criterion Points
Q≥40 ms 2
Q≥30 ms 1 
(n=9) had persistent LV dysfunction while three (27.3%) of patients in the mild LV dysfunction had persistent LV dysfunction while 8 (72.7%) of them had reversible LV dysfunction, that is all patients with reversible LV dysfunction were in the mild LV dysfunction group. A comparison of Group 1 and Group 2 revealed that a history of anthracycline chemotherapy and hypertension were significantly more common in patients with trastuzumab-induced left ventricular systolic dysfunction than those without (for both, p<0.05) ( 
DISCUSSION
Breast cancer is the most common cancer type that is responsible for the most cancer-related deaths among women worldwide (1). It has been reported that HER2-positive (HER2+) subtypes constitute 20% of all breast cancer types and are related to poor prognosis. However, with the advent of anti-HER2 targeted therapies, this has started to change. Trastuzumab is a monoclonal antibody that binds to the extracellular domain of HER2 and acts via activation of antibody-dependent cytotoxicity, inhibition of signal conduction, inhibition of neoangiogenesis, and inhibition of repair of treatment-induced DNA injury (23) . Trastuzumab is used alone or in combination as neoadjuvant, adjuvant therapies, and in metastatic disease (24) . Cardiotoxicity is the most important side effect of trastuzumab, which is most commonly seen as asymptomatic LVEF depression or, less commonly as overt congestive heart failure (8) . Available data about trastuzumab cardiotoxicity is limited, and various mechanisms, including angiotensin II upregulation and resulting cell death due to oxidative stress (24) , antiapoptotic protein BCL-XL's downregulation and the proapoptotic protein BCL-XS's upregulation (25) and inability of maintaining sarcomeres' structure and function and dysregulated scavenging mechanism for the proapoptotic oxidative subproducts (26, 27) have been postulated.
Trastuzumab's cardiotoxicity is shown by a variety of echocardiographic methods, of which biplane disks method (modified Simpson's rule) is the most commonly used one, as in our study. Additionally, M-Mode echocardiography, three dimensional echocardiography, speckle tracking echocardiography, and deformation imaging (strain and strain rate), as well as cardiac magnetic resonance imaging, are also utilized (28) (29) (30) . However, most of the above-mentioned techniques are technologically demanding and time-consuming, and associated with increased cost and limited availability. Moreover, most echocardiographic techniques are operator dependent and flawed by a significant inter-observer variability in LVEF measurement. Therefore, simpler, cheap, readily available techniques are needed to assess left ventricular systolic function in trastuzumab-treated patients. Twelve-lead ECG is a simple, rapidly and widely available test relatively independent of operator interpretation. Therefore, it may offer promise in detecting trastuzumab-induced left ventricular systolic dysfunction.
The Selvester score is a 12-lead ECG score that indicates left ventricular infarct size and extent (14) . The original Selvester score is composed of 54 ECG criteria with a total of 32 points.
The subsequently developed modified Selvester score consists of 50 criteria with a total of 31 points (15, 16) . The Selvester score represents the best electrocardiographic approximation of infarct volume (17) . Its role has been shown in a number of disorders and clinical scenarios characterized by myocardial scarring, including ischemic and non-ischemic cardiomyopathy (18, 19) , Chagas disease (20) , and acute myocardial infarction (21) . However, as far as we know, the Selvester score has not been studied in breast cancer patients with trastuzumab-induced left ventricular systolic dysfunction.
In our study, the modified Selvester score did not show any statistically significant difference between the study groups with and without trastuzumab-induced left ventricular systolic dysfunction (Group 1 and Group 2, respectively). However, the patient subgroup with more severely depressed LVEF (LVEF<50%) (Group 1a) had a significantly greater Selvester score compared to both less severely affected patients (LVEF 50-54%) (Group 1b) and the controls (Group 2). These results suggest that the Selvester score was significantly increased among patients with more severe left ventricular systolic dysfunction, who possibly had myocardial scarring. Unfortunately, we had no MRI data to show myocardial scarring in such patients. However, 12 (60%) of those who had LVEF drop had a persistent LVEF drop, and these patients encompassed all the patients in Group 1a (more severe trastuzumab left ventricular systolic dysfunction). Furthermore, all the patients with reversible LV dysfunction had mild LV dysfunction. These findings suggests that as more severe left ventricular systolic function occurs, more scarring or persistent myocardial fibrosis occurs, increasing the Selvester score. This finding is in line with the previous observations where the Selvester score was closely related to myocardial scar after myocardial infarction (14) . In fact, the original definition of trastuzumab-induced left ventricular systolic dysfunction, that is a 10% LVEF drop to below 55% in asymptomatic patients or a 5 percent LVEF drop to below 55% in symptomatic patients, may not necessarily show severe left ventricular injury in every patient. Some patients may temporarily develop such dysfunction, and some due to contractile dysfunction rather than scarring. Additionally, echocardiography, in its all forms, is heavily operator dependent and, thus, may show LVEF variability. In relation to this information, patients with mild LVEF drop may in fact be included as depressed LVEF, which approximated the Selvester scores in both groups, precluding any significant difference between the patient and control groups regarding the Selvester score. However, as subgroup analyses showed a significantly greater Selvester score in patients with more severely depressed LVEF (LVEF<50%), those patients may have true LVEF depression. One may speculate that ECG changes may not occur without, or with small amount of, scarring or fibrosis in the left ventricular myocardium. The Selvester score, as a constellation of ECG parameters, may actually be expected to better delineate any left ventricular systolic dysfunction than single ECG parameters like isolated Q waves, loss of R wave height, or persistent ST elevation. The lack of statistical significance between patients with and without left ventricular systolic dysfunction may have resulted from a lower number of patients with more severely depressed LVEF, thus, limiting our statistical power.
A reduction of the Selvester score in patients with reversible trastuzumab-induced LV dysfunction after normalization of LV function would be a plausible finding. However, when we re-calculated the Selvester score after normalization of LV function and compared it with the initial Selvester score among patients with LV dysfunction, we identified no significant difference between the two scores. This was interpreted in three ways: First, the low number of subjects in reversible LV dysfunction subgroup masked a statistically significant change in the Selvester score; second, the Selvester scores may be similar in patients with and without subtle degrees of LV dysfunction. This hypothesis was indeed corroborated by the lack of statistical significance between the initial Selvester scores of control subjects and those with a minor LV dysfunction; third, some minor degree of LV dysfunction (LVEF 50-54%) may have actually been a measurement difference between independent echocardiographers performing the echocardiographic studies, and, thus, there may have not been true LV dysfunction and/or normalization at all in these patients. Therefore, we could not ascertain the exact role of the Selvester score in reversible trastuzumab-induced LV dysfunction. This issue should be addressed in a study prospective randomized, controlled study.
Our study has some limitations. First, this was a retrospective study with a relatively small study sample. Second, we could not assess posterior ECGs and, therefore, excluded posterior ECG criteria of the ECG leads V1 and V2, which limited the sensitivity of the study. Third, we did not exclude coronary artery disease as the cause of left ventricular systolic dysfunction. However, we determined trastuzumab-induced left ventricular systolic dysfunction on the basis of temporal and clinical features, with coronary artery disease being unlikely in our patients considering the lack of ischemic symptoms, gender (all female), and age (predominantly of middle age) of the study population.
CONCLUSION
The Selvester score assessed from 12-lead ECG may be indicative of severe left ventricular systolic dysfunction evidenced by subnormal LVEF (<50%) among patients receiving trastuzumab therapy. However, patients with less severe left ventricular systolic impairment may not be detected by the Selvester score as they may have no scarring in the left ventricular myocardium but only reversible systolic dysfunction. Further large-scale studies are needed to answer these questions.
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